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Abstract Mesenchymal stem cell (MSC) therapy is being
increasingly used to treat dogs and horses with
naturally-occurring diseases. However these animals also
serve as critical large animal models for ongoing translation
of cell therapy products to the human market. MSC manufac-
ture for clinical use mandates improvement in cell culture
systems to meet demands for higher MSC numbers and re-
moval of xeno-proteins (i.e. fetal bovine serum, FBS). While
serum-free media (SFM) is commercially available, its affects
on MSC phenotype and immunomodulatory functions are not
fully known. The objective of this study was to determine if
specific MSC culture conditions, MSC expansion in
HYPERFlasks® or MSC expansion in a commercially avail-
able SFM, would alter MSC proliferation, phenotype or im-
munomodulatory properties in vitro. MSCs cultured in
HYPERFlasks® were similar in phenotype, proliferative ca-
pacity and immunomodulatory functions to MSCs grown in
standard flasks however MSC yield was markedly increased.
HYPERFlasks® therefore provide a viable option to generate
greater cell numbers in a streamlined manner. Canine and
equine MSCs expanded in SFM displayed similar prolifera-
tion, surface phenotype and inhibitory effect on lymphocyte
proliferation in vitro. However, MSCs cultured in the absence
of FBS secreted significantly less PGE2, and were significant-
ly less able to inhibit IFNγ secretion by activated T-cells.
Immunomodulatory functions altered by expansion in SFM
were species dependent. Unlike equine MSCs, in canine
adipose-derived MSCs, the inhibition of lymphocyte prolifer-
ation was not principally modulated by PGE2. The removal of
FBS from both canine and equine MSC culture systems re-
sulted in altered immunomodulatory properties in vitro and
warrants further investigation prior to moving towards
FBS-free culture conditions.
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Introduction
Adult-derived multipotent mesenchymal stem cells (MSCs)
hold great appeal for regenerative medicine therapeutic ap-
proaches in both human and veterinary medicine given their
potent immunomodulatory and pro-regenerative properties [1,
2]. MSCs are defined in vitro by their morphology, their ex-
pression of a panel of cell surface markers and their potential
to tri-lineage differentiate in vitro into adipose, bone and car-
tilage [3]. MSCs can be harvested from numerous tissue
sources including bone marrow and adipose tissue followed
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by ex vivo expansion of isolated cells [2]. MSCs are being
investigated for their potential clinical application in multiple
disorders including orthopedic injuries and inflammatory/
immune-mediated diseases [2, 4]. A deeper understanding of
canine and equine MSC biology is critical to guide veterinary
clinical trials as well as to assure appropriate translational
research into naturally occurring diseases that could inform
human clinical trials [5–7].
MSCs are traditionally expanded as an adherent monolayer
in medium supplemented with fetal bovine serum (FBS). The
Food and Drug Administration (FDA) requires that MSC
products meet good manufacturing practice (GMP) and en-
courages the use of xeno-protein free culture conditions to
decrease the potential for xeno-protein immune reactions
and transmission of infectious diseases [8]. In addition, previ-
ous studies in human patients suggest that the development of
anti-FBS antibodies in patients after MSC administration may
be associated with attenuated clinical efficacy [9, 10]. FBS
also has high lot-to-lot variability, which makes reproducibil-
ity extremely difficult [11–13]. HumanMSCs maintain differ-
entiation and proliferative capacities in xeno-protein free cul-
ture conditions, however there are also reports of induced
senescence in vitro [11, 14–19]. The use of xeno-protein free
culture conditions for canine and equine MSCs does not alter
osteogenic and adipogenic differentiation potential, but did
lead to inferior MSC proliferation [13]. The effect of serum
free media (SFM) on canine and equine MSC immunomodu-
latory functions has not yet been determined.
In addition to the concerns regarding the use of FBS, there is
an increasing need for the expansion of even greater MSC
numbers for clinical applications [20]. MSC culture in small
tissue-culture flasks is inefficient and requires a significant
amount of time and reagents in order to achieve the required
cell numbers for treatment. Large bioreactors permit the expan-
sion of greater absolute MSC numbers, while greatly reducing
reagent costs and technician time [21, 22]. HYPERFlasks® are
multilayer flasks that use gas permeable chambers coated with
CellBIND® to optimize cell binding. However, the
CellBIND® coating is a novel proprietary substance, and its
effects on canine and equine MSC proliferative capacity and
immunomodulatory properties have not been investigated.
The objectives of this study were to investigate the effects
of xeno-free, and CellBIND® (HYPERFlasks®) culture con-
ditions on canine and equine MSC functions in vitro com-
pared to standard culture conditions. We hypothesized that
MSC expansion in SFM or HYPERFlasks® would not alter
canine or equine MSC proliferation, surface phenotype or
immunomodulatory properties in vitro. We found that SFM
and CellBIND® did not alter MSC proliferation or surface
phenotype and MSCs cultured in both conditions were effec-
tive in inhibiting T-cell proliferation in vitro. However MSCs
cultured in SFM displayed significant alterations in mediator
secretion patterns. Our study suggests that while the use of
CellBIND® coated HYPERFlasks® are suitable for MSC cul-
ture upscale, the use of commercially available SFM needs
closer investigation prior to clinical implementation.
Materials and Methods
Animal Cells
Equine Low passage (P2-P5) bone marrow-derived MSCs
(eMSCs) from 5 horses were obtained from the UC Davis
(UCD) William R. Pritchard Veterinary Medical Teaching
Hospital Regenerative Medicine Laboratory. These samples
were originally submitted for MSC expansion for autologous
patient treatment. Excess eMSCS not used for treatment were
donated for research purposes with written owner consent.
Canine Low passage (P2-P5) fat-derived MSCs from 5 dogs
were obtained from falciform fat collected fromUCDWilliam
R. Pritchard Veterinary Medical Teaching Hospital patients
undergoing routine abdominal surgery. Fat was collected un-
der an approved Institutional Animal Care and Use
Committee and the Clinical Trials Review Board protocol at
UCD. Fat was processed and canine adipose-derived MSCs
(cMSCs) were isolated, expanded and cryopreserved exactly
as previously described [23, 24].
MSC Culture and Expansion
Cryopreserved MSCs were thawed in a 37 °C water bath and
seeded into 1 of 3 different culture conditions. The first group
consisted of standard culture conditions [25, 26]. These cells
were plated at a density of 5000 cells/cm2 into T185 flasks
(Thermo Fisher Scientific, Waltham, MA) in the standard me-
dium [Dulbecco’sModified Eagle’sMedium (DMEM,Gibco,
Invitrogen, Carlsbad, CA) with 10 % FBS (HyClone, Logan,
UT) and 1 % penicillin-streptomycin (Gibco). The second
group consisted of MSCs plated in HYPERFlasks®
(Corning Inc., Tewksbury, MA). These cells were initially
thawed in standard conditions and were then passed into
HYPERFlasks® at 5000 cells/cm2 in standard medium. The
third group consisted of MSCs cultured in SFM.MSCs do not
readily adhere to plastic in the absence of serum. Therefore, in
the third group, MSCs were thawed into flasks (Thermo
Fisher Scientific) that had been coated with bovine fibronectin
(25–50 μg/mL, Biomedical Technologies Inc., Stoughton,
MA) for 24 h after which cells were replated at a density of
5000 cells/cm2 in StemPro® MSC SFM (Gibco) supplement-
ed with 1 % L-glutamine (Gibco) and 1 % Pen/Strep (Gibco).
All MSCs were grown to 70 % confluence in a standard cell
culture incubator conditions (37 °C, 5 % CO2). During expan-
sion, MSCs were monitored daily for morphologic alterations.
Cells cul tured under standard condit ions and in
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HYPERFlasks® were dissociated using 0.05 % trypsin/EDTA
(Gibco) and neutralized with standard media containing FBS.
MSCs grown in SFM were harvested using HyQTase
(HyClone), and resuspended in Dulbecco’s Phosphate
Buffered Saline (DPBS, Gibco).
MSC Proliferation
Equine MSCs and cMSCs were harvested after 4 days of
culture for proliferation studies. At day 4, MSCs were roughly
70 % confluent, and were counted using an automated cell
counter (COULTER® AcT-Diff Cell Counter, Beckman
Coulter Inc., Miami, FL). Cell doubling times were calculated
as previously reported [26]. Absolute numbers were also re-
corded and normalized for differences in flask surface area in
each culture condition.
MSC Phenotype
EquineAfter harvesting, MSCs expanded in each of the three
conditions were washed and incubated with antibodies direct-
ed against CD90 (VMRD, Pullman, WA, clone DH24A) [27,
28], CD44 (AbD Serotec, Raleigh, NC, clone CVS18) [29],
CD29 (Beckman Coulter Inc., clone 4B4LDC9LDH8) [29],
F6B (a pan leukocyte antibody, a generous gift from Dr.
Jeffrey Stott, UCD, School of Veterinary Medicine) [30],
CD86 (BD Biosciences, Franklin Lakes, NJ, clone IT2.2)
[28], MHC I (AbD Serotec; clone CVS22) [31], and MHC
II (AbD Serotec; clone CVS20) [28].
Canine After harvesting, MSCs expanded in each of the 3
conditions were washed and incubated with antibodies direct-
ed against CD90 [23], CD45 [23],MHCII (all fromLeukocyte
Antigen Biology Laboratory, UCD, School of Veterinary
Medicine, clone CA1.4G8, CA12.10C12, CA2.1C12 respec-
tively) [23], CD34 (BD Biosciences, clone RAM34) [23],
CD54 (a generous gift from C. Smith, Houston, TX, clone
CL18.1D8) [23] and CD44 (R&D Systems, Minneapolis,
MN, clone 69-S5).
Equine MSC and cMSC phenotype were evaluated via
flow cytometry (Cytomics, Beckman Coulter FC500,
Hialeah, FL). Flow cytometry data was analyzed using
FlowJo flow cytometry software (Tree Star Inc., Ashland,
OR).
Mixed Leukocyte Reaction (MLR)
Equine Peripheral blood was collected into tubes containing
acid–citrate dextrose (ACD; BD Biosciences) via jugular ve-
nipuncture. T lymphocytes were enriched from peripheral
blood mononuclear cells (PBMCs) using nylon wool and plat-
ed exactly as previously described [27]. To inhibit MSC pro-
liferation, MSCs were irradiated (10Gy, Varian 2100C linear
accelerator, Varian Medical Systems Inc., Palo Alto, CA) and
kept on ice before plating in each corresponding medium.
Enriched T-cells were stimulated with phytohemagglutin at
5 μg/mL (PHA, Sigma-Aldrich, St. Louis, MO). Enriched
T-cells from donor horses and allogeneic MSCs were plated
exactly as previously described [27, 32].
Canine Peripheral blood was collected into tubes containing
sodium heparin (Vacutainer®, BD Biosciences) via jugular
venipuncture. PBMCs were obtained using a discontinuous
Ficoll gradient and were plated with allogeneic cMSCs exact-
ly as previously described [24]. PBMCs were used for these
assays in canines due to the large blood volume necessary to
isolate lymphocytes using a nylon wool gradient. PMBCs
were activated with 5 μg/mL concanavalin A (Con-A,
Sigma-Aldrich).
After 3 days of co-culture, wells were treated with 1 mM
Bromodeoxyuridine (BrdU, BD Biosciences). Twenty-four
hours post BrdU treatment, leukocytes were collected and
cells were stained for nuclear BrdU incorporation per manu-
facturer directions (FITC BrdU Flow Kit, BD Biosciences)
and read by flow cytometry.
At the time of leukocyte collection, culture supernatant was
collected, centrifuged and stored at −80 °C, as previously
described [27] for the measurement of secreted mediators.
The following ELISA kits were used: equine PGE2
(Prostaglandin E2 Parameter Assay Kit; R&D Systems)
[33], canine PGE2 (Prostaglandin E2 Express EIA kit
(Monoclonal); Cayman Chemical Company, Ann Arbor,
MI) [24], equine interleukin10 (IL-10; Equine IL-10 Duoset;
R&D Systems) [32], equine interferon-γ (IFNγ; Equine IFNγ
Duoset; R&D Systems) [34] and equine tumor necrosis
factor-α (TNFα; Equine TNFα screening kit; Thermo Fisher
Scientific) [34]. Equine IL-6 was measured exactly as previ-
ously described [35]. ELISA plates were read spectrophoto-
metrically on a microplate reader with Gen5 software
(Synergy HT Multi-Mode, Biotek, Winooski, VT). Canine
TNFα, IFNγ, IL-6 and IL-10 were determined using a canine
cytokine magnetic bead panel (Milliplex Map, EMD
Millipore, Billerica, MA) per manufacturer instructions and
were read on a Bio-Plex 200 using Bio-Plex Manager 4.1.1
software (Bio-Rad Laboratories, Hercules, CA).
In some assays the cyclooxygenase (COX) inhibitor indo-
methacin was used to chemically block PGE2 production.
Indomethacin was added to MLR assays during plating at a
concentration of 10 μM (Sigma-Aldrich) exactly as previous-
ly described [32].
Statistical Analysis
Results are presented as median and interquartile range. Data
were analyzed using non-parametric Mann-Whitney-
Wilcoxon t-test (GraphPad InStat version 3.06 for Windows,
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La Jolla, CA). P < 0.05 was considered statistically
significant.
Results
Equine and Canine MSC Cultured in HYPERFlasks®
Did not Display Altered Proliferative Capacity,
Immune-Suppressive Qualities or Mediator Profile
Equine No alterations in the cell doubling times of eMSCs
cultured in HYPERFlasks® (2.4 ± 0.3 days) were observed
when compared to standard conditions (2.0 ± 0.6 days, Fig.
1a). However there was a marked increase in the absolute
n umbe r o f eMSCs p r o d u c e d a f t e r c u l t u r e i n
HYPERFlasks®. This increase was due to the increased cul-
ture surface area (1721 cm2). Cells plated in HYPERFlasks®
yielded ~4× more eMSCs than cells plated in standard condi-
tions (44 × 106 ± 24 × 106 total cells compared to
9.3 × 106 ± 5 × 106 total cells).
We have previously published the immunomodulatory
phenotype of equine MSCs cultured in standard conditions
including results from MLR experiments [27, 32]. We found
that equine MSCs inhibit activated lymphocyte proliferation
via the induction of cell cycle arrest, inhibition IFNγ and
TNFα secretion from activated T cells and the secretion of
PGE2 and IL-6, among other mediators [27, 32]. The goal of
the current project was to determine if this constellation of
immune properties would be maintained after culture expan-
sion in a more relevant cell expansion system and after expan-
sion in SFM that did not contain FBS. Equine MSCs cultured
in HYPERFlasks® maintained their ability to inhibit lympho-
cyte proliferation compared to eMSCs cultured in standard
conditions (Fig. 1b). Mediator analysis of supernatants from
MLR experiments demonstrated there was no difference in
IL-6 (Fig. 1c) or PGE2 (Fig. 1d) secretion by activated
eMSC cultured in HYPERFlasks® compared with eMSCs
cultured in standard conditions. Equine MSCs grown in
HYPERFlask® were as effective as eMSC cultured in stan-
dard conditions in inhibiting TNFα (Fig. 1e) and IFNγ (Fig.
1f) secretion by activated T-cells. However MSCs cultured in
HYPERFlasks® secreted significantly higher concentrations
of (P < 0.05) IL-10 (Fig. 1f) compared to eMSC cultured in
standard conditions.
Canine As with eMSCs, we have previously published the
immunophenotype of canine MSCs after culture in standard
conditions in our laboratory [24, 36]. As such, we focused on
if the culture expansion of cMSCs in a larger, more relevant
flask system and in the absence of FBS would result in a
different immunophenotype than standard culture. cMSCs
cultured in HYPERFlasks® generally mirrored findings with
eMSCs. Whereas cMSC doubling time was not altered when
cultured in HYPERFlasks® (2 ± 0.6 days) compared with
standard culture conditions (1.6 ± 0.2 days, Fig. 2a),
HYPERFlasks® yielded ~18× more cells due to increased
surface area (39 × 106 ± 1.7 × 106 total cells as compared to
2.3 × 106 ± 6 × 106 in two flasks cultured under standard
conditions). cMSC cultured in HYPERFlasks® were as effec-
tive as cMSC cultured in standard conditions in inhibiting
PBMC proliferation (Fig. 2b). There was no difference in
the ability of cMSC to secrete IL-6 (Fig. 2c) and PGE2
(Fig. 2d) and to inhibit TNFα (Fig. 2e), IFNγ (Fig. 2f) and
IL-10 (Fig. 2g) secretion by activated PBMCs for MSCs cul-
tured in HYPERFlasks® compared to standard conditions.
MSC Surface Phenotype is not Altered by Culture
Conditions
Equine In all culture conditions, eMSCs were positive for
CD90, CD44 and CD29. Similarly, eMSCs did not express
MHC II, CD86 or F6B (pan leukocyte marker) regardless of
cell culture condition (Table 1).
Canine In all culture conditions, cMSCs were positive
for CD44, CD54 and CD90. cMSCs did not express
CD34, MHCII or CD45 (Table 1). Thus expansion of
MSCs in either HYPERFlask® or in SFM did not alter
standard cell surface protein expression in either eMSCs
or cMSCs.
MSC Proliferation Capacity is not Altered by Culture
in SFM
Equine eMSCs had population doubling times of 2.4 ± 0.3
and 2.4 ± 0.9 days in standard conditions and in SFM condi-
tions, respectively (Fig. 3a). There was no statistical difference
in doubling time of eMSCs between culture with and without
FBS (p > 0.05).
Canine The population doubling times for cMSCs were
1.4 ± 0.3 and 1.7 ± 0.8 days in standard conditions and in
SFM conditions, respectively (Fig. 3b). There was no statisti-
cal difference in doubling time between cMSC cultured in
standard media when compared to the SFM condition
(p > 0.05).
SFM Culture Conditions Alter eMSC
Immunomodulatory Properties in Vitro
While SFM-eMSC were as effective as eMSC cultured in
standard conditions in their capacity to inhibit T-cell pro-
liferation in vitro (Fig. 4a), secreted protein concentra-
tions in MLR supernatant were altered when SFM-
eMSC were compared with eMSC cultured under
standard conditions. While IL-6 secretion by activated
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MSC (Fig. 4b) was not altered by eMSC culture method,
the secretion of IL-10 (Fig. 4c) and PGE2 (Fig. 4d)
displayed reciprocal inverse changes. IL-10 secretion
was markedly and significantly (P < 0.05) increased when
activated T-cells were co-cultured with eMSCs grown
without FBS however PGE2 concentration was markedly
and significantly (P < 0.05) decreased. Moreover, the con-
centrations of the pro-inflammatory mediators, TNFα
(Fig. 4e) and IFNγ (Fig. 4f) were significantly higher
when activated T-cells were co-cultured with eMSCs cul-
tured in the absence of FBS compared to eMSCs cultured
with FBS.
SFM Culture Conditions Alter cMSC
Immunomodulatory Properties in Vitro
Similar to eMSCs, cMSCs cultured in the absence of FBS
were as effective in inhibiting PBMC proliferation in vitro
as cMSCs grown under standard conditions. However, as in
eMSCs, secreted protein concentration within the superna-
tants of these MLR experiments was altered by culture meth-
od. IL-6 and IL-10 secretion by activated cMSCs was not
changed by the absence of FBS (Fig. 5a, b). However PGE2
secretion by activated cMSCs was markedly and significantly
(P < 0.05) decreased in cMSCs cultured in the absence of FBS
Fig. 1 Equine MSC cultured in HYPERFlasks® did not display altered
proliferative capacity, immune-suppressive qualities or mediator profile.
No significant alterations in cell proliferation (population doubling time
in days) of equine MSCs cultured in standard conditions were noted as
compared to equine MSCs cultured in HYPERFlasks® (a). Similarly
equine MSCs cultured in HYPERFlasks® maintain the ability to inhibit
mitogen induced lymphocyte proliferation (b) and maintain a similar
mediator profile as compared to MSCs cultured in standard conditions.
HYPERFlask® cultured equine MSCs, in the presence of stimulated
lymphocytes, produce IL-6 (c), PGE2 (d) and inhibit TNFα (e) and IFNγ
(f) to the same degree as MSCs cultured in standard conditions. IL-10
production by stimulated lymphocytes however, was not reduced to the
same amount asMSCs cultured in standard conditions (g). Data presented
as a median and interquartile range
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compared with cMSCs cultured in standard conditions.
cMSCs cultured without FBS were similar in the ability to
modulate TNFα secretion (Fig. 5e) by Con-A activated
PBMC, compared to cMSCs in standard conditions.
Fig. 2 Canine MSC cultured in HYPERFlasks® also do not display
altered proliferative capacity, immune-suppressive qualities or mediator
profile. Canine MSCs cultured in HYPERFlasks® maintain similar
proliferative rate (population doubling time in days) (a) and the ability
to inhibit mitogen induced lymphocyte proliferation (b) as compared to
canine MSCs in standard culture conditions. HYPERFlask® cultured
canine MSCs, upon activation, produce IL-6 (c), PGE2 (d) and inhibit
TNFα (e), IFNγ (f) and IL-10 (g) to the same degree as canine MSC
cultured in standard conditions. Data presented as a median and
interquartile range
Table 1 Surface protein markers as determined by flow cytometry
Equine Canine
Marker Standard (% +) HYPERFIasks® (% +) SFM (% +) Marker Standard (% +) HYPERFIasks® (% +) SFM (% +)
CD29 96 ± 0.1 95 ± 1.2 96 ± 1.2 CD54 97 ± 0.0 98 ± 0.0 97 ± 0.0
CD44 95 ± 0.7 95 ± 0.2 95 ± 1.1 CD44 98 ± 0.0 98 ± 0.0 99 ± 0.0
CD9O 83 ± 14.4 92 ± 1.9 88 ± 5.9 CD9O 91 ± 0.0 88 ± 0.0 96 ± 0.0
MHC II 0 ± 0.0 1 ± 0.6 4 ± 2.1 MHC II 0 ± 0.0 0 ± 0.0 0 ± 0.0
CD86 0 ± 0.0 0 ± 0.2 0 ± 0.0 CD34 1 ± 0.0 0 ± 0.0 1 ± 0.0
F6B 0 ± 0.0 0 ± 0.2 2 ± 0.9 CD45 0 ± 0.0 0 ± 0.0 0 ± 0.0
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However IFNγ concentration was markedly and significantly
(P < 0.05) higher when activated PBMCs were co-cultured
with cMSCs in the absence of FBS.
MSC-Derived PGE2 Modulated Equine Lymphocyte
Proliferation but was not Responsible for the Inhibition
of Canine Lymphocyte Proliferation
We have previously reported that activated eMSCs from a
variety of tissue sources inhibit T lymphocyte proliferation
through a predominantly PGE2 mediated pathway [32]. This
was determined through the use of indomethacin, a COX in-
hibitor, to block PGE2 synthesis and secretion. Given that
eMSCs and cMSC cultured in the absence of FBS retained
their capacity to inhibit lymphocyte proliferation in spite of
secreting significantly less PGE2, we determined if PGE2 still
mediated the inhibitory effect in MSCs cultured in SFM. In
agreement with previous findings, blocking PGE2 production
in eMSCs restored lymphocyte proliferation in standard con-
ditions (Fig. 6a, p < 0.05). Similarly, blocking PGE2 synthesis
in eMSCs cultured in the absence of FBS also inhibited T-cell
proliferation (Fig. 6a, p > 0.05) suggesting that while the se-
cretion of PGE2 is markedly decreased by eMSCs cultured
without FBS, it is still the primary soluble factor that facilitates
the inhibition of equine T-cell proliferation. In this study,
blocking PGE2 synthesis by cMSCs did not restore lympho-
cyte proliferation in standard or SFM conditions (Fig. 6b).
Discussion
In this study we determined the immunomodulatory and phe-
notypic consequences of a high yield, high performance tissue
culture flask and FBS-free culture conditions for the culture of
canine and equine MSCs. Both animal species are of great
veterinary and translational research significance [7]. We de-
termined that the expansion of canine and equine MSCs in
HYPERFlasks® did not adversely alter MSC phenotype or
immunomodulatory function and markedly improved MSC
yield by providing 4–18× more MSCs in the same amount
of time as traditional culture methods. This increase in MSC
yield will allow more efficient banking of cells for research
and clinical use. These findings are consistent with human
MSC literature and may suggest that expansion systems are
suitable for large scale and GMP-grade clinical use [21, 37,
38]. While optimal dosing of MSC for clinical applications
has not been fully defined in literature, there is evidence that
MSCs may act in a dose response fashion [20]. Large upscale
production and banking ofMSCwill provide an accessible off
the shelf product that may potentially be used for high dose
clinical use pending further dose response studies.
Although the expansion of cMSCs and eMSCs in the ab-
sence of FBS did not alter MSC proliferation, surface pheno-
type or their capacity to inhibit T-cell proliferation in vitro,
MSC immunomodulatory properties were significantly al-
tered. It is important to note that while serum was removed
from the SFM condition, bovine fibronectin was used as the
minimal foreign component to allow for MSC adherence.
Fibronectin is an extracellular matrix glycoprotein involved
in cell adherence. Given MSC proliferation was not alerted
in SFM conditions, fibronectin likely had no significant ef-
fects on MSCs in culture. Both cMSCs and eMSCs expanded
in SFM secreted significantly less PGE2 than cells grown in
FBS-containing media. cMSCs and eMSCs were also less
able to inhibit pro-inflammatory cytokine production. These
findings are concerning as PGE2 is a key mediator by which
MSCs exert many of their immunomodulatory and trophic
effects [1, 2, 39]. Prior to the removal or substitution of FBS
from culture systems, a clearer understanding of how
species-specific MSCs activate, signal and secrete their tro-
phic and immunomodulatory mediators will be critical.
In our experiments, IL-10 concentration was inversely re-
lated to PGE2 concentration in eMSCs. Notably, eMSC cul-
tured in HYPERFlasks® also significantly increased IL-10
production. These observations prompted us to hypothesize
that in the relative absence of PGE2 secretion by activated
MSCs, an alternative cellular pathway could be engaged
which results in increased secretion (likely by activated T
regulatory cells) of the potent immunoregulatory cytokine,
IL-10. We further hypothesized that while the inhibition of
Fig. 3 MSC proliferation capacity is not altered by culture in SFM. Cell
proliferation (population doubling time in days) of eMSCs (a) and
cMSCs (b) cultured in standard conditions and in SFM conditions. No
significant alterations were found in cell doubling time between MSC
cultured in standard and SFM conditions. Data presented as a median
and interquartile range
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PGE2 synthesis in standard culture conditions will rescue lym-
phocyte proliferation, such a rescue will not be seen in SFM
conditions. Our results demonstrate that while IL-10 secretion
was markedly induced in SFM conditions, PGE2 was still the
primary effector mediator inhibiting equine lymphocyte pro-
liferation, suggesting that a basal level of PGE2 in an MLR
setting is sufficient to induce an inhibitory effect on T-cell
proliferation. A similar response to PGE2 blocking was not
Fig. 4 SFM culture conditions alter eMSC immunomodulatory
properties in vitro. Stimulated lymphocytes were co-culturedwith eMSCs
in standard conditions and in SFM. A BrdU incorporation assay was used
to record lymphocyte proliferation. Baseline unstimulated lymphocyte
proliferation is indicated as a dashed line. No significant alterations were
observed in the ability of eMSC to inhibit mitogen induced lymphocyte
proliferation (a). MSC secretion of IL-6 was not altered by culture in
serum free media (b). However, levels of IL-10 (c) and production of
PGE2 (d) by activated MSCs in SFM was significantly altered in an
inverse fashion, as compared to MSCs cultured in standard conditions.
Inhibition of the pro-inflammatory mediators TNFα (e), and IFNγ (f) by
stimulated lymphocytes was significantly altered in MSC cultured in
SFM conditions. Data are presented as a median and interquartile range.
Bars with an asterisk indicate significant differences in median values
when compared to MSCs cultured in standard conditions (p < 0.05,
Mann-Whitney-Wilcoxon)
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seen in cMSCs, suggesting that PGE2 may play a less signif-
icant role in inhibiting lymphocyte proliferation in this spe-
cies. These findings are consistent with previous studies in our
laboratory [24] but are in disagreement with other studies that
indicate the necessary role of PGE2 for cMSC mediated im-
mune regulation [40, 41]. These discrepancies may be ex-
plained by differing methodologies, variable enrichment of
T-cells versus PBMCs and perhaps MSC tissue source. Most
Fig. 5 SFM culture conditions alter cMSC immunomodulatory
properties in vitro. Stimulated lymphocytes were co-culturedwith cMSCs
in standard conditions and in SFM. A BrdU incorporation assay was used
to record lymphocyte proliferation. Baseline unstimulated lymphocyte
proliferation is indicated as a dashed line. No significant alterations were
observed in the ability of cMSCs to inhibit mitogen induced lymphocyte
proliferation (a). MSC secretion of IL-6 was not altered by culture in
serum free media (b). Similarly, levels of IL-10 were also unaltered in
MSC co-cultures in standard and SFM conditions (c). PGE2 production
by activated cMSCs in SFM was significantly decreased as compared to
MSC cultured in standard conditions (d). No changes were observed in
inhibition of TNFα (e), however a significant increase was observed in
levels of IFNγ (f) in MSC co-culture in SFM conditions. Data are pre-
sented as a median and interquartile range. Bars with an asterisk indicate
significant differences in median values when compared to MSCs cul-
tured in standard conditions (p < 0.05, Mann-Whitney-Wilcoxon)
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notably, in our hands, cMSCs co-cultured with stimulated
PBMCs produce nearly 10× the levels of PGE2 as compared
to previous reports [40, 41]. Results from this in vitro study
suggest that PGE2 secretion is not the primary mechanism by
which MSCs mediate immunomodulation in dogs. An
in-depth investigation of the role that MSC-derived PGE2
plays in lymphocyte regulation in dogs is warranted.
In this study, we discovered a disconnect between the in-
hibition of lymphocyte proliferation and a corresponding de-
crease in the proinflammatory mediators IFNγ and TNFα
typically noted in a MLR [24, 32]. MSCs cultured in SFM
markedly inhibited lymphocyte proliferation however the se-
cretion of the pro-inflammatory mediators IFNγ (canine and
equine) and TNFα (equine) was poorly inhibited. These data
further suggest that in the absence of serum in the culture
media, MSC immunomodulatory properties are compro-
mised. The use of SFM for human MSC culture has remained
controversial [11]. There have been reports that human MSCs
can readily be expanded in SFM, while other groups argue
that for MSCs to be expanded in serum free conditions, cyto-
kines and other growth factors must be supplemented [11].
Our data coincides with previous reports, which suggest that
while MSCs can proliferate in serum free conditions,
sustained immunomodulatory properties in vitro are most po-
tent in the presence of FBS [42–44].
The objectives of this study were to investigate potential
modifications to ex vivo MSC expansion that would increase
MSC yield and potentially permit removal of FBS to decrease
the risk of FBS-induced immune response and culture hetero-
geneity. Our results suggest that HYPERFlask® provide a
suitable scale up alternative to standard MSC culture, while
substantially minimizing technician time and reagents
required for culture of larger MSC doses. We also demonstrat-
ed that MSCs can be expanded successfully to achieve higher
absolute cell numbers using HYPERFlask® without altering
basic MSC characteristics including proliferation, phenotype
or immunomodulatory functions. It can also be concluded that
while canine and equineMSCs can be successfully cultured in
a commercially available SFM media that does not alter sur-
face phenotype or proliferative capacity, differing results in
the mediator secretion profile warrant further investigation
before the use of this media should be recommended for use
in the clinical setting.
In conclusion, both eMSCs and cMSCs can be cultured in
HYPERFlask® vessels to generate greater absolute numbers
of MSC without altering MSC characteristics. Culturing
MSCs in a commercially available SFM did not alter MSC
proliferative capacity, surface protein phenotype or immune
functions, however the cytokine profile was drastically al-
tered. These findings warrant further studies for the use of
xeno-free mediums for the culture of veterinary MSCs.
These results also highlight species differences of MSCs and
the need to further elucidate changes in mechanisms by which
MSCs downregulate inflammation in different species.
ACD Acid-citrate dextrose, BrdU Bromodeoxyuridine,
cMSC Adipose derived canine mesenchymal stem cell,
DMEM Dulbecco’s Modified Eagle Medium, DPBS Dulbecco
phosphate buffered saline, ELISA Enzyme-linked immunosor-
bent assay, eMSC Bone marrow derived equine mesenchymal
stem cell, FBS Fetal bovine serum, GMP Good manufacturing
practice, IFNγ Interferon-γ, MSC Mesenchymal stem cell,
PBMC Peripheral blood mononuclear cells, PGE2
Prostaglandin E2, SFM Serum freemedia, TNFαTissue necrosis
factor α, UCD University of California, Davis
Fig. 6 Inhibition of PGE2 synthesis restores equine lymphocyte
proliferation but does not restore canine lymphocyte proliferation.
Blocking of PGE2 production by equine (a) and canine (b) MSCs using
the COX inhibitor indomethacin in a mixed leukocyte reaction setting.
Blocking equine PGE2 restored T-cell proliferation in both standard and
SFM conditions (p < 0.05, a). Blocking PGE2 production by canine
MSCs did not restore PBMC proliferation in both standard and SFM
conditions (b). Data are presented as a median and interquartile range.
Bars with an asterisk indicated a significant change in the median of %
BrdU positive lymphocytes as compared to standard MLR conditions
(p < 0.05, Mann-Whitney-Wilcoxon)
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